Researchers Awarded $15 Million to Study Heart Valve Disease

The American Heart Association (AHA) has awarded a four‑year, $15 million research initiative focused on earlier detection and slowing progression of valvular heart disease.

The program, titled the Strategically Focused Research Network on Earlier Detection and Delaying Progression of Valvular Heart Disease, funds collaborative research involving three lead centers: Mass General Brigham Heart and Vascular Institute (Boston), Cincinnati Children’s Hospital Medical Center, and the University of Pittsburgh.

The awards began April 1, 2026.

The article provides organizational context, lists lead investigators at each center, and situates the program within the AHA’s broader portfolio of Strategically Focused Research Networks.

The initiative’s explicit aim is to improve understanding of how to diagnose and treat heart valve disease, with emphasis on earlier detection and interventions that delay disease progression.

The AHA frames this priority in the context of rising global prevalence and substantial mortality associated with valvular disease.

The organization highlights that valvular heart disease frequently advances without symptoms, limiting opportunities for timely treatment, and that earlier identification could expand therapeutic options and reduce complications.

The AHA also positions the network as a mechanism to support innovative, multidisciplinary scientific inquiry into patient‑relevant gaps in diagnosis and management.

The article does not detail the exact allocation per center or the administrative structure for coordinating intercenter projects.

Hilaire, Ph.D., FAHA, is listed as director of the Center for Integrative Valve Science and associate professor of medicine.

Specific project descriptions, methodologies, sample sizes, or timelines beyond the award start date were not provided in the source.

• Funding mechanism: The program is one of the AHA’s Strategically Focused Research Networks, an established funding approach that supports multi‑center scientific collaborations targeted at preselected strategic issues identified by the AHA Board of Directors.
• Duration and scale: Awards are structured as four‑year grants totaling $15 million distributed across the three funded centers.
• Participating institutions and named leaders:
• Mass General Brigham Heart and Vascular Institute, Boston: Elena Aikawa, M.D., Ph.D., FAHA, is identified as director of the Heart Valve Translational Research Program at Brigham and Women’s.
• Cincinnati Children’s Hospital Medical Center: Andrea Beaton, M.D., M.S., FAHA, professor of pediatrics at the University of Cincinnati and pediatric cardiologist at Cincinnati Children’s, is named among the investigative leads.
• University of Pittsburgh: Cynthia St.
• Planned activities: The awards will support collaborative research projects across the three centers.

In the United States, the condition is reported to contribute to over 57,000 deaths annually, according to the AHA statistics referenced.

The AHA commentary included in the article emphasizes that untreated valvular disease can progress to adverse clinical states such as heart failure, arrhythmia, recurrent hospitalizations, impaired quality of life, and premature death.

The article stresses that earlier diagnosis before severe symptom onset could broaden management options and reduce downstream complications.

• Burden: The article cites the AHA’s 2026 Heart Disease and Stroke Statistics to note that more than 80 million people worldwide are living with some form of heart valve disease and that prevalence is increasing.
• Disease characterization: The source summarizes valvular heart disease as dysfunction of one or more of the heart’s four valves, producing either stenosis that restricts forward blood flow or regurgitation that allows backward flow.
• Natural history and detection challenges: The AHA statement in the article highlights that valvular disease becomes more prevalent with advancing age and frequently progresses without clinically overt symptoms, which contributes to under‑recognition.

Previous networks have examined diverse topics including prevention, hypertension, women’s cardiovascular health, heart failure, obesity, vascular disease, atrial fibrillation, arrhythmias and sudden cardiac death, cardiometabolic disease and type 2 diabetes, health technology, cardio‑oncology, chronic psychosocial stress, inflammation in cardiovascular health, and cardiovascular‑kidney‑metabolic syndrome.

The AHA is described as the largest non‑government, non‑profit funder of heart and brain health research in the United States.

• Network history: The AHA has established 19 Strategically Focused Research Networks to date, each addressing a different strategic scientific priority.
• Organizational investment: The source reports that the AHA has invested nearly $300 million toward establishing the 19 networks and that, since 1949, the organization has funded more than $6.1 billion in cardiovascular, cerebrovascular, and brain‑health research.

Rosen, M.D., FAHA, AHA volunteer president and executive director of the Katz Institute for Women’s Health (Northwell Health), is quoted emphasizing the growing prevalence of valve disease, its frequent silence in early stages, and the potential value of research that promotes early detection.

Rosen also references the AHA’s Heart Valve Initiative and the Target: Aortic Stenosis quality improvement program as existing efforts to improve care, framing the network as an extension of these activities focused on earlier stages of disease.

• Stacey E.

No specific diagnostic tests, biomarkers, imaging modalities, or therapeutic interventions under study are described.

• The source contains no data on study outcomes, safety findings, interim results, or planned measures of efficacy or effectiveness.

The article does not specify how findings will be translated into practice, nor does it detail plans for dissemination, implementation, or interaction with clinical quality improvement programs beyond general alignment with existing AHA initiatives.

• The AHA frames the network as a vehicle for “innovative, cutting‑edge scientific exploration” and anticipates that multi‑disciplinary collaboration across basic, clinical, and population/behavioral science will generate new ways to diagnose, treat, and prevent valvular disease.

There is no information on projected timelines for deliverables, planned recruitment strategies, target populations (beyond a general focus on heart valve disease), or mechanisms for data sharing and coordination among sites.

The article does not report potential conflicts of interest, independent oversight mechanisms, or peer‑review status of the awards beyond AHA Board approval.

• The article provides limited methodological detail: it does not enumerate specific hypotheses, study designs, endpoints, or funding distribution among centers.
• Absence of data: No preliminary results or baseline data from the funded projects are presented.